Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Inventory (2017 - 2025)

Ptc Therapeutics (PTCT) has 9 years of Inventory data on record, last reported at $79.6 million in Q4 2025.

  • For Q4 2025, Inventory rose 243.39% year-over-year to $79.6 million; the TTM value through Dec 2025 reached $79.6 million, up 243.39%, while the annual FY2025 figure was $79.6 million, 243.39% up from the prior year.
  • Inventory reached $79.6 million in Q4 2025 per PTCT's latest filing, up from $52.7 million in the prior quarter.
  • Across five years, Inventory topped out at $79.6 million in Q4 2025 and bottomed at $14.8 million in Q3 2022.
  • Average Inventory over 5 years is $28.2 million, with a median of $24.9 million recorded in 2023.
  • The widest YoY moves for Inventory: up 243.39% in 2025, down 27.89% in 2025.
  • A 5-year view of Inventory shows it stood at $15.9 million in 2021, then skyrocketed by 37.54% to $21.8 million in 2022, then surged by 40.21% to $30.6 million in 2023, then decreased by 24.15% to $23.2 million in 2024, then skyrocketed by 243.39% to $79.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $79.6 million in Q4 2025, $52.7 million in Q3 2025, and $34.1 million in Q2 2025.